This is a working overview of Somatotroph, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
| Property | Value | Notes |
|---|---|---|
| Primary target | Growth hormone-releasing hormone receptor | Located on anterior pituitary somatotroph cells. |
| Receptor class | G protein-coupled receptor | Activation increases intracellular cyclic AMP. |
| Main downstream hormone | Growth hormone and insulin-like growth factor 1 | Growth hormone release precedes IGF-1 elevation. |
| Primary studied effect | Reduction in visceral adipose tissue | Measured by computed tomography in clinical trials. |
| Approximate half-life | 26–38 minutes after subcutaneous administration | Values vary by assay and study population. |
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
=== World War II === With the outbreak of World War II, weaponization of botulinum toxin was investigated at Fort Detrick in Maryland. Carl Lamanna and James Duff developed the concentration and crystallization techniques that Edward J. Schantz used to create the first clinical product. When the Army's Chemical Corps was disbanded, Schantz moved to the Food Research Institute in Wisconsin, where he manufactured toxin for experimental use and provided it to the academic community. The mechanism of botulinum toxin action – blocking the release of the neurotransmitter acetylcholine from nerve endings – was elucidated in the mid-20th century, and remains an important research topic. Nearly all toxin treatments are based on this effect in various body tissues.
== Death row conditions == A 1978 newspaper article described the death row section of the original Changi Prison as consisting of 24 cells arranged in a horse shoe shaped block around an open air grassy exercise yard. The exercise area itself was enclosed in steel bars and had a wire mesh roof to prevent escape by helicopter. Amnesty International reports that death row inmates are housed in cells of roughly three square metres (32 square feet). Walls make up three sides, while the fourth is made up of vertical bars. They are equipped with a toilet, a sleeping mat, and a bucket for washing. Exercise is permitted twice a day for half an hour at a time. Four days before the execution, the condemned is allowed to watch television or listen to the radio. Special meals of their choice are also cooked, if within the prison budget. In 1994, inmates had a budget of S$22 for their last meal. One documented last meal of an inmate was the last meal order of Tangaraju Suppiah, who asked for chicken rice, ice cream soda, nasi biryani and Milo-flavoured sweets before his hanging, while another was John Martin Scripps, who ordered a pizza and a cup of hot chocolate before his execution. Visiting rights are increased from one 20-minute visit per week to a maximum of four hours each day, though no physical contact is allowed with any visitors. In addition, two days before an execution, an inmate is allowed to have a photo shoot and be given their own clothes to pose during a photoshoot; the photo will be given to their families as remembrance.
A medical specialty is a branch of medical practice that is focused on a defined group of patients, diseases, skills, or philosophy. Examples include those branches of medicine that deal exclusively with children (pediatrics), cancer (oncology), laboratory medicine (e.g. pathology), or primary care (family medicine). After completing medical school or another form of basic training, physicians or surgeons and other clinicians usually further their medical education in a specific specialty of medicine by completing a multiple-year residency to become a specialist.
SSRIs are structurally diverse with clear variations in their pharmacodynamic and pharmacokinetic profiles, which leads to differences among them in their half-lifes, clinical activity, adverse effects and drug interactions, which explains the differences in their efficacy and tolerability among patients. However, all SSRIs are clinically equal when it comes to their efficacy over time. Table 2 Comparison of the chemical properties of SSRI drugs
Sources: en.wikipedia.org
=== Planets === Though many other civilisations in the Culture books live on planets, the Culture as currently developed has little direct connection to on-planet existence. Banks has written that he presumes this to be an inherent consequence of space colonisation, and a foundation of the liberal nature of the Culture. A small number of home worlds of the founding member-species of the Culture receive a mention in passing, and a few hundred human-habitable worlds were colonised (some of them terraformed) before the Culture elected to turn towards artificial habitats, preferring to keep the planets it encounters wild. Since then, the Culture has come to look down on terraforming as inelegant, ecologically problematic and possibly even immoral. Less than one per cent of the population of the Culture lives on planets, and many find the very concept somewhat bizarre. This attitude is not absolute though; in Consider Phlebas, some Minds suggest testing a new technology on a "spare planet" (knowing that it could be destroyed in an antimatter explosion if unsuccessful). One could assume – from Minds' usual ethics – that such a planet would have been lifeless to start with. It is also quite possible, even probable, that the suggestion was not made in complete seriousness.
== Career == In 2001, Nigam founded the Swansea University Maggot Research Group, of which she is a director. The group focuses on therapeutic applications of the medicinal maggot Lucilia sericata. She then became an associate professor at Swansea University. In 2018, Nigam was promoted to professor which included a move from the research to the innovation and engagement strand. Nigam fulfills many roles outside of her permanent academic position. In 2007, she became a member of the Welsh Wound Network group, an enterprise which aims to support the clinical development of wound healing science. In April 2014, she was an elected participant of the Welsh Crucible Programme. Nigam is an elected Fellow of the Royal Entomological Society (FRES).
Placing a wedge in the felling cut can prevent a sitback from pinching the saw. Freeing: Working a badly fallen tree that may have become trapped in other trees. Working out maximum tension locations to decide the safest way to release tension, and a winch may be needed in complicated situations. To avoid cutting straight through a tree in tension, one or two cuts at the tension point of sufficient depth to reduce tension may be necessary. After tension releases, cuts are made outside the bend. Limbing: Cutting the branches off the log. The operator must be able to properly reach the cut to avoid kickback. Bucking: Cross-cutting the felled log into sections. Setup is made to avoid binding the chainsaw within the changing log tensions and compressions. Safe bucking is started at the log high-side and then sections worked offside, toward the butt end. The offside log falls and allows for gravity to help prevent binds. The log's kerf movement while cutting can help to indicate binds. Additional equipment (lifts, bars, wedges, and winches) and special cutting techniques can help prevent binds. Binds: This is when the chainsaw is at risk or is stuck in the log compression. A log bound chainsaw is unsafe and must be carefully removed to prevent equipment damage. Top bind – The tension area on log bottom, compression on top. Bottom bind – The tension area on log top, compression on bottom. Side bind – Sideways pressure exerted on the log. End bind – Weight compresses the log's entire cross-section.
Sources: en.wikipedia.org
Qullqa's were generally built of masonry in connected groups on dry hillsides to take advantage of drainage and winds. Their size and design varied from region to region, but round qullqas were typically used to store maize and rectangular qullqas were used to store freeze-dried potatoes ("chuño") and other root crops. Qullqas had a ventilation system consisting of a channel beneath the floor to permit air to enter and an opening under the roof to allow air to escape. The interior diameter of an average small qullqa was 3.23 metres (10.6 ft); larger qullqas have a diameter of around 3.5–4.0 metres (11.5–13.1 ft). These smaller qullqa could have held 3.7 cubic metres (100 US bushels) of maize, and larger qullqa could have held about 5.5 cubic metres (160 US bushels) of maize. Most of the remains of qullqas near Cuzco have disappeared due to urban expansion and development over the centuries. The largest remaining number of qullqas is in the Mantaro River valley between the present days cities of Huancayo and Jauja, Peru. This broad valley, some 60 kilometres (37 mi) long contains about 65,000 hectares (160,000 acres) of cultivatable lands ranging in elevation from 3,200 metres (10,500 ft) to 4,250 metres (13,940 ft), the highest elevation at which cultivation was possible in this area. The Mantaro Valley was one of the largest and most fertile high-altitude areas of the Inca Empire. 2,573 qullqas have been found in the valley by archaeologists.
=== Insect-resistant crops === Bacillus thuringiensis is a bacterium that naturally produces a protein (Bt toxin) with insecticidal properties. The bacterium has been applied to crops as an insect-control strategy for many years, and this practice has been widely adopted in agriculture and gardening. Recently, plants have been developed that express a recombinant form of the bacterial protein, which may effectively control some insect predators. Environmental issues associated with the use of these transgenic crops have not been fully resolved.
== Function == SLC15A1is localized to the brush border membrane of the intestinal epithelium and mediates the uptake of di- and tripeptides from the lumen into the enterocytes. This protein plays an important role in the uptake and digestion of dietary proteins. This protein also facilitates the absorption of numerous peptidomimetic drugs. Peptide transporter 1 functions in nutrient and drug transport have been studied using intestinal organoids.
Colonial imperialism is the inevitable consequence in the course of economic relations among countries when the domestic price-fixing of monopoly capitalism has voided profitable competition in the capitalist homeland. The ideology of New Imperialism, rationalised as a civilising mission, allowed the exportation of high-profit investment capital to undeveloped countries with uneducated, native populations (sources of cheap labour), plentiful raw materials for exploitation (factors for manufacture) and a colonial market to consume the surplus production which the capitalist homeland cannot consume. The example is the European Scramble for Africa (1881–1914) in which imperialism was safeguarded by the national military. To secure the economic and settler colonies, foreign sources of new capital-investment-profit, the imperialist state seeks either political or military control of the limited resources (natural and human). The First World War (1914–1918) resulted from such geopolitical conflicts among the empires of Europe over colonial spheres of influence. For the colonised working classes who create the wealth (goods and services), the elimination of war for natural resources (access, control, and exploitation) is resolved by overthrowing the militaristic capitalist state and establishing a socialist state because a peaceful world economy is feasible only by proletarian revolutions that overthrow systems of political economy based upon the exploitation of labour.
Sources: en.wikipedia.org
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.
It does not act directly on adipose tissue as a primary mechanism. Instead, it increases endogenous growth hormone, which then influences lipolysis and fat distribution. The reduction in visceral fat is an indirect pharmacodynamic effect.
Tesamorelin acts upstream at the pituitary to amplify natural pulsatile growth hormone release. Growth hormone injections provide exogenous hormone and bypass pituitary regulation. The two approaches therefore differ in feedback control and hormonal dynamics.
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.